Glucose as a Mediator of Self-control Performances in Patients With Schizophrenia
1 other identifier
interventional
100
1 country
1
Brief Summary
The research aims to investigate the relationship between self-control ability and blood glucose level in schizophrenic patients. The main purpose of the present study is to explore whether the close relationship of blood glucose and self-regulatory strength observed in healthy individuals, is applicable to schizophrenic patients. More specifically, the current study aims
- to investigate whether the exertion of self-control reduces blood glucose,
- to examine whether low level of blood glucose deteriorates subsequent self-control performances
- to examine whether restoring the glucose level eliminates these impairments, in schizophrenic patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable schizophrenia
Started Apr 2012
Shorter than P25 for not_applicable schizophrenia
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 22, 2012
CompletedFirst Posted
Study publicly available on registry
March 26, 2012
CompletedStudy Start
First participant enrolled
April 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2013
CompletedMarch 26, 2012
March 1, 2012
1 year
March 22, 2012
March 23, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Blood Glucose Level
baseline, after depleting task
self control tasks (handgrip, stroop, figure tracing task)
after 12-minutes metabolizing phase
Study Arms (4)
Glucose & Depleting
EXPERIMENTALparticipants will perform in a depleting task and receive a glucose drink
Glucose & non-depleting
PLACEBO COMPARATORparticipants will perform in a non-depleting task and receive a glucose drink
Placebo & depleting
NO INTERVENTIONparticipants will perform in a depleting task and receive a placebo drink
Placebo & non depleting
NO INTERVENTIONparticipants will perform in a non depleting task and receive a placebo drink
Interventions
participants will receive a drink rich in glucose
Eligibility Criteria
You may qualify if:
- Aged 15 or above
- DSM-IV diagnosis of schizophrenia, schizoaffective disorder, schizophreniform psychosis, brief psychosis, psychosis NOS or delusional disorder
- Cantonese-speaking Chinese
- Ability to understand the nature of the study and sign informed consent
You may not qualify if:
- Organic Brain disorder
- Known history of intellectual disability
- Priority Follow Up (Subtarget or Target)
- All allergic to any sugar or artificial sweeteners
- Diabetics
- Physical Disability
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The University of Hong Konglead
- Queen Mary Hospital, Hong Kongcollaborator
Study Sites (1)
The University of Hong Kong
Hong Kong, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eric YH Chen, MD
The University of Hong Kong
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 22, 2012
First Posted
March 26, 2012
Study Start
April 1, 2012
Primary Completion
April 1, 2013
Study Completion
April 1, 2013
Last Updated
March 26, 2012
Record last verified: 2012-03